PURPOSE: The objective is to describe progressive changes in hearing and cochlear function in children and adolescents treated with platinum-based chemotherapy and to begin preliminary evaluation of the feasibility of extended high-frequency audiometry and distortion product otoacoustic emissions for ototoxicity monitoring in children. PATIENTS AND METHODS: Baseline and serial measurement of conventional pure-tone audiometry (0.5 to 8 kHz) and evoked distortion product otoacoustic emissions (DPOAEs) were conducted for 32 patients age 8 months to 20 years who were treated with cisplatin and/or carboplatin chemotherapy. Seventeen children also had baseline and serial measurement of extended high-frequency (EHF) audiometry (9 to 16 kHz). Audiologic data were analyzed to determine the incidence of ototoxicity using the American Speech-Language-Hearing Association criteria, and the relationships between the different measures of ototoxicity. RESULTS: Of the 32 children, 20 (62.5%) acquired bilateral ototoxicity in the conventional frequency range during chemotherapy treatment, and 26 (81.3%) had bilateral decreases in DPOAE amplitudes and dynamic range. Of the 17 children with EHF audiometry results, 16 (94.1%) had bilateral ototoxicity in the EHF range. Pilot data suggest that EHF thresholds and DPOAEs show ototoxic changes before hearing loss is detected by conventional audiometry. CONCLUSION: EHF audiometry and DPOAEs have the potential to reveal earlier changes in auditory function than conventional frequency audiometry during platinum chemotherapy in children.
PURPOSE: The objective is to describe progressive changes in hearing and cochlear function in children and adolescents treated with platinum-based chemotherapy and to begin preliminary evaluation of the feasibility of extended high-frequency audiometry and distortion product otoacoustic emissions for ototoxicity monitoring in children. PATIENTS AND METHODS: Baseline and serial measurement of conventional pure-tone audiometry (0.5 to 8 kHz) and evoked distortion product otoacoustic emissions (DPOAEs) were conducted for 32 patients age 8 months to 20 years who were treated with cisplatin and/or carboplatin chemotherapy. Seventeen children also had baseline and serial measurement of extended high-frequency (EHF) audiometry (9 to 16 kHz). Audiologic data were analyzed to determine the incidence of ototoxicity using the American Speech-Language-Hearing Association criteria, and the relationships between the different measures of ototoxicity. RESULTS: Of the 32 children, 20 (62.5%) acquired bilateral ototoxicity in the conventional frequency range during chemotherapy treatment, and 26 (81.3%) had bilateral decreases in DPOAE amplitudes and dynamic range. Of the 17 children with EHF audiometry results, 16 (94.1%) had bilateral ototoxicity in the EHF range. Pilot data suggest that EHF thresholds and DPOAEs show ototoxic changes before hearing loss is detected by conventional audiometry. CONCLUSION: EHF audiometry and DPOAEs have the potential to reveal earlier changes in auditory function than conventional frequency audiometry during platinum chemotherapy in children.
Authors: Sienna R Burke; Abigail R Rogers; Stephen T Neely; Judy G Kopun; Hongyang Tan; Michael P Gorga Journal: Ear Hear Date: 2010-08 Impact factor: 3.570
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Angela C Garinis; Douglas H Keefe; Lisa L Hunter; Denis F Fitzpatrick; Daniel B Putterman; Garnett P McMillan; Jeffrey A Gold; M Patrick Feeney Journal: Ear Hear Date: 2018 Jan/Feb Impact factor: 3.570
Authors: Kelly M Reavis; Garnett McMillan; Donald Austin; Frederick Gallun; Stephen A Fausti; Jane S Gordon; Wendy J Helt; Dawn Konrad-Martin Journal: Ear Hear Date: 2011-02 Impact factor: 3.570
Authors: Johnnie K Bass; Kristin R Knight; Torunn I Yock; Kay W Chang; Douglas Cipkala; Satkiran S Grewal Journal: Pediatr Blood Cancer Date: 2016-02-29 Impact factor: 3.167